Literature DB >> 6260313

Serum 1,25-dihydroxyvitamin D concentration in hypophosphatemic vitamin D-resistant rickets.

E E Delvin, F H Glorieux.   

Abstract

Fasting serum 1 alpha, 25-dihydroxyvitamin D [1,25-(OH)2D] levels were measured in 3 groups of hypophosphatemic vitamin D-resistant rickets (VDRR) patients; those untreated; those treated with vitamin D and phosphate; and those treated with 1,25-(OH)2D3 and phosphate. In the untreated patients, the mean 1,25-(OH)2D level was higher than in our age-matched control group. Except for one at 66 pg/ml, individual values were however within normal limits. Long term vitamin D2 therapy was accompanied by a slight but significant decrease in 1,25-(OH)2D concentrations; nonetheless the levels remained within the normal range. In the third group of patients, the concentration of 1,25-(OH)2D rose to supranormal levels when sampling was done 1-3 hours after administration of the hormone, decreasing rapidly to levels below that of normal subjects when the specimens were collected 12-24 hours later. Our data show that an alteration of the vitamin D activation pathway is unlikely to be part of the pathogenic mechanism underlying the VDRR condition.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6260313     DOI: 10.1007/bf02409431

Source DB:  PubMed          Journal:  Calcif Tissue Int        ISSN: 0171-967X            Impact factor:   4.333


  14 in total

1.  A sensitive, precise, and convenient method for determination of 1,25-dihydroxyvitamin D in human plasma.

Authors:  J A Eisman; A J Hamstra; B E Kream; H F DeLuca
Journal:  Arch Biochem Biophys       Date:  1976-09       Impact factor: 4.013

2.  Use of phosphate and vitamin D to prevent dwarfism and rickets in X-linked hypophosphatemia.

Authors:  F H Glorieux; C R Scriver; T M Reade; H Goldman; A Roseborough
Journal:  N Engl J Med       Date:  1972-09-07       Impact factor: 91.245

3.  Competitive protein-binding radioassay for 25-hydroxycholecalciferol.

Authors:  J G Haddad; K J Chyu
Journal:  J Clin Endocrinol Metab       Date:  1971-12       Impact factor: 5.958

4.  Serum 1,25-dihydroxyvitamin D levels in normal subjects and in patients with hereditary rickets or bone disease.

Authors:  C R Scriver; T M Reade; H F DeLuca; A J Hamstra
Journal:  N Engl J Med       Date:  1978-11-02       Impact factor: 91.245

5.  Hypercalcemia during long-term treatment with 1,25-dihydroxyvitamin D3 in hypoparathyroidism.

Authors:  N H Bell; S Epstein; P H Stern
Journal:  N Engl J Med       Date:  1979-11-22       Impact factor: 91.245

6.  Calcium-dependent, parathyroid hormone-independent regulation of 1,25-dihydroxyvitamin D.

Authors:  U Trechsel; J A Eisman; J A Fischer; J P Bonjour; H Fleisch
Journal:  Am J Physiol       Date:  1980-08

7.  Serum parathyroid hormone in X-linked hypophosphatemia.

Authors:  C Arnaud; F Glorieux; C Scriver
Journal:  Science       Date:  1971-08-27       Impact factor: 47.728

8.  Supranormal 25-hydroxyvitamin D and subnormal 1,25-dihydroxyvitamin D: their role in X-linked hypophosphatemic rickets.

Authors:  R W Chesney; R B Mazess; P Rose; A J Hamstra; H F DeLuca
Journal:  Am J Dis Child       Date:  1980-02

9.  Loss of a parathyroid hormone-sensitive component of phosphate transport in X-linked hypophosphatemia.

Authors:  F Glorieux; C R Scriver
Journal:  Science       Date:  1972-03-03       Impact factor: 47.728

10.  Stimulation of 1,25-dihydroxyvitamin D production by parathyroid hormone and hypocalcemia in man.

Authors:  B Lund; O H Sørensen; B Lund; J E Bishop; A W Norman
Journal:  J Clin Endocrinol Metab       Date:  1980-03       Impact factor: 5.958

View more
  15 in total

1.  X linked hypophosphataemia: treatment, height gain, and nephrocalcinosis.

Authors:  G S Reusz; P F Hoyer; M Lucas; H P Krohn; J H Ehrich; J Brodehl
Journal:  Arch Dis Child       Date:  1990-10       Impact factor: 3.791

Review 2.  Vitamin D-endocrine system.

Authors:  N H Bell
Journal:  J Clin Invest       Date:  1985-07       Impact factor: 14.808

3.  Calcitonin stimulation of renal 25-hydroxyvitamin D-1 alpha-hydroxylase activity in hypophosphatemic mice. Evidence that the regulation of calcitriol production is not universally abnormal in X-linked hypophosphatemia.

Authors:  T Nesbitt; B Lobaugh; M K Drezner
Journal:  J Clin Invest       Date:  1987-01       Impact factor: 14.808

4.  Serum 1,25-dihydroxyvitamin D levels in subjects with X-linked hypophosphatemic rickets and osteomalacia.

Authors:  K W Lyles; A G Clark; M K Drezner
Journal:  Calcif Tissue Int       Date:  1982-03       Impact factor: 4.333

5.  Bone response to phosphate and vitamin D metabolites in the hypophosphatemic male mouse.

Authors:  P J Marie; R Travers; F H Glorieux
Journal:  Calcif Tissue Int       Date:  1982-03       Impact factor: 4.333

6.  Abnormal regulation of renal 25-hydroxyvitamin D-1 alpha-hydroxylase activity in the X-linked hypophosphatemic mouse.

Authors:  B Lobaugh; M K Drezner
Journal:  J Clin Invest       Date:  1983-02       Impact factor: 14.808

7.  Effects of phosphate and 1,25(OH)2D3 on in vitro bone collagen synthesis in the hypophosphatemic mouse.

Authors:  B Ecarot-Charrier; F H Glorieux
Journal:  Calcif Tissue Int       Date:  1983-05       Impact factor: 4.333

8.  Metabolites of vitamin D in normal and X-linked hypophosphatemic mice.

Authors:  R A Meyer; M H Meyer; R W Gray
Journal:  Calcif Tissue Int       Date:  1984-12       Impact factor: 4.333

9.  Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice.

Authors:  Martin Y H Zhang; Daniel Ranch; Renata C Pereira; Harvey J Armbrecht; Anthony A Portale; Farzana Perwad
Journal:  Endocrinology       Date:  2012-02-14       Impact factor: 4.736

10.  Influence of magnesium supplementation on bone turnover in the normal young mouse.

Authors:  P J Marie; R Travers; E E Delvin
Journal:  Calcif Tissue Int       Date:  1983-09       Impact factor: 4.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.